Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)

Market Cap	2.68B
Revenue (ttm)	763.75M
Net Income (ttm)	136.88M
Shares Out	51.15M
EPS (ttm)	2.67
PE Ratio	19.57
Forward PE	20.67
Dividend	0.94 (1.80%)
Ex-Dividend Date	Jul 8, 2024

Volume	116,998
Average Volume	126,052
Open	52.15
Previous Close	51.95
Day's Range	52.15 - 53.45
52-Week Range	50.45 - 94.80
Beta	0.48
RSI	41.65
Earnings Date	May 9, 2025

About BME:ROVI

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+,...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1946
• Employees: 2,197
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: ROVI

Financial Performance

In 2024, BME:ROVI's revenue was 763.75 million, a decrease of -7.93% compared to the previous year's 829.51 million. Earnings were 136.88 million, a decrease of -19.64%.